110 related articles for article (PubMed ID: 15078146)
1. Protein phosphatase inhibition: structure based design. Towards new therapeutic agents.
Sakoff JA; McCluskey A
Curr Pharm Des; 2004; 10(10):1139-59. PubMed ID: 15078146
[TBL] [Abstract][Full Text] [Related]
2. Okadaic acid: the archetypal serine/threonine protein phosphatase inhibitor.
Dounay AB; Forsyth CJ
Curr Med Chem; 2002 Nov; 9(22):1939-80. PubMed ID: 12369865
[TBL] [Abstract][Full Text] [Related]
3. The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?
McCluskey A; Ackland SP; Gardiner E; Walkom CC; Sakoff JA
Anticancer Drug Des; 2001 Dec; 16(6):291-303. PubMed ID: 12375882
[TBL] [Abstract][Full Text] [Related]
4. Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
McCluskey A; Sim AT; Sakoff JA
J Med Chem; 2002 Mar; 45(6):1151-75. PubMed ID: 11881984
[No Abstract] [Full Text] [Related]
5. Small molecule inhibitors of serine/threonine protein phosphatases.
McCluskey A; Sakoff JA
Mini Rev Med Chem; 2001 May; 1(1):43-55. PubMed ID: 12369990
[TBL] [Abstract][Full Text] [Related]
6. 19-epi-okadaic acid, a novel protein phosphatase inhibitor with enhanced selectivity.
Cruz PG; Daranas AH; Fernández JJ; Norte M
Org Lett; 2007 Aug; 9(16):3045-8. PubMed ID: 17630753
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of cytostatin analogues.
Bialy L; Waldmann H
Chem Commun (Camb); 2003 Aug; (15):1872-3. PubMed ID: 12932009
[TBL] [Abstract][Full Text] [Related]
8. Viewing serine/threonine protein phosphatases through the eyes of drug designers.
Zhang M; Yogesha SD; Mayfield JE; Gill GN; Zhang Y
FEBS J; 2013 Oct; 280(19):4739-60. PubMed ID: 23937612
[TBL] [Abstract][Full Text] [Related]
9. Strategies for Targeting Serine/Threonine Protein Phosphatases with Small Molecules in Cancer.
Zhang Q; Fan Z; Zhang L; You Q; Wang L
J Med Chem; 2021 Jul; 64(13):8916-8938. PubMed ID: 34156850
[TBL] [Abstract][Full Text] [Related]
10. Structure-based drug design of new leads for phosphatase research.
Combs AP
IDrugs; 2007 Feb; 10(2):112-5. PubMed ID: 17285463
[TBL] [Abstract][Full Text] [Related]
11. A pharmacophore model of tautomycin, an inhibitor of protein phosphatases 1 and 2A.
Ubukata M; Koshino H; Yamasaki C; Fujita K; Isono K
J Antibiot (Tokyo); 1997 Oct; 50(10):801-7. PubMed ID: 9402983
[No Abstract] [Full Text] [Related]
12. Pharmacophore identification: the case of the ser/thr protein phosphatase inhibitors.
Colby DA; Chamberlin AR
Mini Rev Med Chem; 2006 Jun; 6(6):657-65. PubMed ID: 16787376
[TBL] [Abstract][Full Text] [Related]
13. A targeted library of small-molecule, tyrosine, and dual-specificity phosphatase inhibitors derived from a rational core design and random side chain variation.
Rice RL; Rusnak JM; Yokokawa F; Yokokawa S; Messner DJ; Boynton AL; Wipf P; Lazo JS
Biochemistry; 1997 Dec; 36(50):15965-74. PubMed ID: 9398331
[TBL] [Abstract][Full Text] [Related]
14. Regulation of p42 mitogen-activated-protein kinase activity by protein phosphatase 2A under conditions of growth inhibition by epidermal growth factor in A431 cells.
Chajry N; Martin PM; Cochet C; Berthois Y
Eur J Biochem; 1996 Jan; 235(1-2):97-102. PubMed ID: 8631373
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of protein phosphatases-1 and -2A with acanthifolicin. Comparison with diarrhetic shellfish toxins and identification of a region on okadaic acid important for phosphatase inhibition.
Holmes CF; Luu HA; Carrier F; Schmitz FJ
FEBS Lett; 1990 Sep; 270(1-2):216-8. PubMed ID: 2171991
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of serine/threonine phosphoprotein phosphatases alter circadian properties in Gonyaulax polyedra.
Comolli J; Taylor W; Rehman J; Hastings JW
Plant Physiol; 1996 May; 111(1):285-91. PubMed ID: 8685268
[TBL] [Abstract][Full Text] [Related]
17. Spirastrellolide A: revised structure, progress toward the relative configuration, and inhibition of protein phosphatase 2A.
Williams DE; Lapawa M; Feng X; Tarling T; Roberge M; Andersen RJ
Org Lett; 2004 Jul; 6(15):2607-10. PubMed ID: 15255702
[TBL] [Abstract][Full Text] [Related]
18. Effect of tumor necrosis factor-alpha on insulin-stimulated mitogen-activated protein kinase cascade in cultured rat skeletal muscle cells.
Begum N; Ragolia L; Srinivasan M
Eur J Biochem; 1996 May; 238(1):214-20. PubMed ID: 8665940
[TBL] [Abstract][Full Text] [Related]
19. A model for binding of structurally diverse natural product inhibitors of protein phosphatases PP1 and PP2A.
Gupta V; Ogawa AK; Du X; Houk KN; Armstrong RW
J Med Chem; 1997 Sep; 40(20):3199-206. PubMed ID: 9379439
[TBL] [Abstract][Full Text] [Related]
20. Self-assembly of okadaic acid as a pathway to the cell.
Daranas AH; Cruz PG; Creus AH; Norte M; Fernández JJ
Org Lett; 2007 Oct; 9(21):4191-4. PubMed ID: 17867692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
